Bacteria Containment Immune Response Medicine 
Pharmaceutical Technology
MAY 25, 2023
The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The response was more powerful than that generated by MenACWY-D – a licensed quadrivalent meningococcal vaccine marketed by GSK.
Drug Discovery World
NOVEMBER 4, 2022
Researchers from the University of Oxford investigated whether previously identified correlates of protection associated with risk of full-blown TB disease could also be associated with risk of infection from the bacteria that causes TB. infection in infants who became infected with the bacteria but did not progress to active TB.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
AUGUST 26, 2020
Macrophages are white blood cells that specialize in the detection, phagocytosis and destruction of bacteria and other harmful organisms. In other words, when fighting bacteria, the macrophages are programmed to be pro-inflammatory. However, when they are programmed to be anti-inflammatory, they can help decrease inflammation.
The Pharma Data
DECEMBER 13, 2020
Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. CAMBRIDGE, Mass. , 14, 2020 /PRNewswire/ — Synlogic, Inc. Synlogic’s President and Chief Executive Officer.
Pfizer
FEBRUARY 16, 2023
Food and Drug Administration (FDA) and Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in 2025, pending successful completion of the Phase 3 studies and subject to the agreement of these regulatory agencies to proposed modifications of the clinical trial plan. FDA in July 2017.
The Pharma Data
OCTOBER 19, 2020
Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. among adults 65 years of age or older.
The Pharma Data
DECEMBER 31, 2020
Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford.
Expert insights. Personalized for you.
195 
Let's personalize your content